Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

被引:36
|
作者
Del Prete, Gregory Q. [1 ]
Lifson, Jeffrey D. [1 ]
Keele, Brandon F. [1 ]
机构
[1] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Leidos Biomed Res Inc, Frederick, MD USA
基金
美国国家卫生研究院;
关键词
macaque; simian-human immunodeficiency virus; simian immunodeficiency virus; vaccine challenge; SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS MACAQUES; MENSTRUAL-CYCLE; NEUTRALIZATION SENSITIVITY; DISEASE PROGRESSION; CYNOMOLGUS MACAQUES; PARTIAL PROTECTION; SIV CHALLENGES; INFECTION; SHIV;
D O I
10.1097/COH.0000000000000311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 50 条
  • [31] Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection
    Kling, Heather M.
    Norris, Karen A.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (10): : 1586 - 1595
  • [32] Encouraging vaccine results from primate models of HIV type 1 infection
    Schultz, A
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 : S261 - S263
  • [33] Novel prime-boost vaccine strategies against HIV-1
    Excler, Jean-Louis
    Kim, Jerome H.
    EXPERT REVIEW OF VACCINES, 2019, 18 (08) : 765 - 779
  • [34] Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials
    Hudgens, MG
    Self, SG
    Chiu, YL
    Russell, ND
    Horton, H
    McElrath, MJ
    JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 288 (1-2) : 19 - 34
  • [35] The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?
    Berneman, Zwi N.
    MOLECULAR THERAPY, 2016, 24 (11) : 1896 - 1897
  • [36] Response to willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial
    Halpern, SD
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) : 412 - 412
  • [37] Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies
    Del Prete, Gregory Q.
    Lifson, Jeffrey D.
    CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) : 262 - 272
  • [39] Immunogenicity of lyophilized MVA vaccine for HIV-1 in mice model
    Zhang Zi-zhe
    Jiang Chun-lai
    Yu Xiang-hui
    Lou Chao-ping
    Zhao Dong-hai
    Wu Yong-ge
    Jin Ying-hua
    Liu Cheng-shan
    Kong Wei
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2007, 23 (03) : 329 - 332
  • [40] Towards an HIV-1 vaccine: lessons from studies in macaque models
    Hulskotte, EGJ
    Geretti, AM
    Osterhaus, ADME
    VACCINE, 1998, 16 (9-10) : 904 - 915